 pEGFP- PDL1 |
|||
| PVT10283 | Lifescience Market | 2 ug | EUR 301 |
 (PDL1/2746) Antibody) PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC402746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF640R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC402746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF640R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCB2746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Biotin conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCB2746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Biotin conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC552746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF555 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC552746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF555 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC702746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF770 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC702746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF770 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC432746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF543 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC432746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF543 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC472746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF647 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC472746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF647 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCAP2746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCAP2746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC802746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC802746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC682746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF568 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC682746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF568 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC812746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC812746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC882746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF488A conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC882746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF488A conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC612746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF660R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC612746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF660R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC942746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC942746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCA2746-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), APC conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNUB2746-100 | Biotium | 100uL | EUR 264 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Concentration: 0.2mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNUB2746-500 | Biotium | 500uL | EUR 513 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Concentration: 0.2mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNUM2746-50 | Biotium | 50uL | EUR 405 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), 1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCH2746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCH2746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC042746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405S conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC042746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405S conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC052746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405M conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC052746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405M conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCP2746-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), PerCP conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCR2746-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), RPE conjugate, Concentration: 0.1mg/mL |
|||
 Human Cancer PrimaCell15: Skin Cancer Cells |
|||
| 2-96038 | CHI Scientific | 1 Kit | Ask for price |
 (6His) inducible lentiviral particles) h CD274 (PDL1) (6His) inducible lentiviral particles |
|||
| LVP1077 | GenTarget | 1x107 IFU/ml x 200ul | EUR 451 |
|
Description: Pre-made over-expression lentivirus for expressing C-terminal His-Taggedhuman target: CD274 (6His) (human CD274 molecule), [alternative names: B7-H; B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_014143.3. It contains a RFP-Blasticidin dual selection marker. |
|||
 Protein) Human Cancer Antigen CA125 (Ovarian Cancer) Protein |
|||
| abx061590-100kU | Abbexa | 100 kU | EUR 1205 |
 Human Cancer PrimaCell15: Skin Cancer Cells Growth Medium |
|||
| 9-46038 | CHI Scientific | 5 x 100 ml | Ask for price |
 Bladder Cancer Exosome |
|||
| P141-BL | 101Bio | - | Ask for price |
 Breast Cancer Exosome |
|||
| P141-BR | 101Bio | - | Ask for price |
 Colorectal Cancer Exosome |
|||
| P141-CO | 101Bio | - | Ask for price |
 Kidney Cancer Exosome |
|||
| P141-KN | 101Bio | - | Ask for price |
 Lung Cancer Exosome |
|||
| P141-LG | 101Bio | - | Ask for price |
 Liver Cancer Exosome |
|||
| P141-LV | 101Bio | - | Ask for price |
 Nasopharyngeal Cancer Exosome |
|||
| P141-NA | 101Bio | - | Ask for price |
 Prostate Cancer Exosome |
|||
| P141-PR | 101Bio | - | Ask for price |
 Thyroid Cancer Exosome |
|||
| P141-TH | 101Bio | - | Ask for price |
 (6His, GFP-Puro) inducible lentiviral particles) h CD274 (PDL1) (6His, GFP-Puro) inducible lentiviral particles |
|||
| LVP1077-GP | GenTarget | 1x107 IFU/ml x 200ul | EUR 451 |
|
Description: Pre-made over-expression lentivirus for expressing C-terminal His-Taggedhuman target: CD274 (6His) (human CD274 molecule), [alternative names: B7-H; B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_014143.3. It contains a GFP-Puromycin dual selection marker. |
|||
 Human Cancer Tissue Preparation Buffer 15: Skin Cancer Cells |
|||
| 9-80038 | CHI Scientific | 1 x 100 ml | Ask for price |
 Exosome) Melanoma (skin cancer) Exosome |
|||
| P141-MN | 101Bio | - | Ask for price |